

Animesh D Pardanani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6742541/publications.pdf>

Version: 2024-02-01

354
papers

16,090
citations

20759

60
h-index

18075

120
g-index

354
all docs

354
docs citations

354
times ranked

8725
citing authors

#	ARTICLE	IF	CITATIONS
1	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2022, 196, 975-983.	1.2	14
2	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2022, 97, E35.	2.0	18
3	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<sc>MDS</sc>) but not in <sc>MDS</sc>/<sc>MPN</sc>. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	6
4	Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
5	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. <i>Blood Cancer Journal</i> , 2022, 12, 26.	2.8	5
6	<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. <i>Haematologica</i> , 2022, 107, 1189-1192.	1.7	3
7	Erythrocytosis associated with <i>EPAS1</i>, <i>HIF2A</i>, <i>EGLN1</i>, <i>PHD2</i>, <i>VHL</i>, <i>EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience. <i>Haematologica</i> , 2022, 107, 1201-1204.	1.7	4
8	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. <i>American Journal of Hematology</i> , 2022, 97, 630-637.	2.0	11
9	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	10
10	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. <i>Blood Cancer Journal</i> , 2022, 12, 44.	2.8	9
11	Mast cell sarcoma: 2 Mayo Clinic cases. <i>American Journal of Hematology</i> , 2022, 97, 1381-1383.	2.0	5
12	Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. <i>Cancer Research</i> , 2022, 82, 749-763.	0.4	20
13	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20â€‰mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	7
14	A dynamic 3â€‰factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 1127-1134.	2.0	7
15	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€” A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 1-9.	1.2	8
16	Young platelet millionaires with essential thrombocythemia. <i>American Journal of Hematology</i> , 2021, 96, E93-E95.	2.0	11
17	Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2021, 96, 508-525.	2.0	104
18	Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E146-E150.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 49.	2.8	28
20	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA±venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021, 96, E108-E111.	2.0	7
21	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 46.	2.8	6
22	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 54.	2.8	5
23	Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. <i>American Journal of Hematology</i> , 2021, 96, E182-E184.	2.0	11
24	Mutations and thrombosis in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021, 11, 77.	2.8	26
25	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. <i>Leukemia</i> , 2021, 35, 2166-2181.	3.3	35
26	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021, 96, 781-789.	2.0	46
27	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021, 11, 122.	2.8	7
28	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. <i>British Journal of Haematology</i> , 2021, 195, 133-137.	1.2	2
29	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021, 195, 244-248.	1.2	37
30	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021, 195, 413-416.	1.2	9
31	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. <i>American Journal of Hematology</i> , 2021, 96, 1472-1480.	2.0	20
32	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021, 96, E464-E468.	2.0	9
33	High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. <i>American Journal of Hematology</i> , 2021, 96, 1647-1654.	2.0	8
34	JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. <i>Blood</i> , 2021, 138, 2886-2889.	0.6	12
35	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. <i>Blood</i> , 2021, 138, 1492-1492.	0.6	0
36	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021, 138, 1267-1267.	0.6	0

#	ARTICLE	IF	CITATIONS
37	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. <i>Blood</i> , 2021, 138, 238-238.	0.6	2
38	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 3651-3651.	0.6	1
39	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021, 138, 3657-3657.	0.6	1
40	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021, 138, 3368-3368.	0.6	1
41	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. <i>Blood</i> , 2021, 138, 3630-3630.	0.6	0
42	Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR-ABL1</i> like (<sc>P</sc>hiladelphia chromosome like) <sc>B</sc>-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E68-E72.	2.0	4
43	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020, 34, 1407-1421.	3.3	68
44	Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151412.	0.6	9
45	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521.	2.0	83
46	81-Year-Old Man With Insomnia and Pruritus. <i>Mayo Clinic Proceedings</i> , 2020, 95, e59-e64.	1.4	0
47	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68.	2.8	8
48	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600.	0.6	17
49	Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. <i>American Journal of Hematology</i> , 2020, 95, 1224-1225.	2.0	4
50	A population-based study of chronic eosinophilic <sc>leukemia</sc> not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020, 95, E257.	2.0	6
51	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020, 34, 2519-2524.	3.3	25
52	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020, 189, 291-302.	1.2	134
53	Phenotypic correlates and prognostic outcomes of <sc><i>TET2</i></sc> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. <i>American Journal of Hematology</i> , 2020, 95, E86-E89.	2.0	3
54	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. <i>American Journal of Hematology</i> , 2020, 95, E114-E117.	2.0	14

#	ARTICLE	IF	CITATIONS
55	<scp>WHO</scp> defined chronic eosinophilic leukemia, not otherwise specified (<scp>CEL</scp>,) Tj ETQq1 1 0.784314 rgBT /Overlo 95, E172-E174.	2.0	26
56	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40.	0.6	10
57	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1248-1269.	2.3	21
58	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	0.6	0
59	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	0.6	0
60	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	0.6	0
61	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20.	0.6	0
62	Phenotypic heterogeneity associated with germline <i>GATA2</i> haploinsufficiency: a comprehensive kindred study. Leukemia and Lymphoma, 2019, 60, 3282-3286.	0.6	4
63	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	1.4	6
64	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12.	2.8	52
65	Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234.	2.0	9
66	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. Leukemia, 2019, 33, 2522-2553.	3.3	1
67	World Health Organization class-independent risk categorization in mastocytosis. Blood Cancer Journal, 2019, 9, 29.	2.8	12
68	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
69	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779.	2.0	51
70	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11.	2.8	9
71	Essential Thrombocythemia. New England Journal of Medicine, 2019, 381, 2135-2144.	13.9	106
72	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Mutations and prognosis in myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019, 60, 1112-1113.	0.6	1
74	Calculator of free point-of-care prognostication in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2019, 94, E99-E101.	2.0	0
75	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. <i>Leukemia</i> , 2019, 33, 780-785.	3.3	4
76	The germline <i>JAK2</i> GGCC (46/1) haplotype and survival among 414 molecularly annotated patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2019, 94, 299-305.	2.0	11
77	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019, 94, 286-290.	2.0	10
78	Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. <i>American Journal of Hematology</i> , 2019, 94, E1-E2.	2.0	16
79	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019, 94, 5-9.	2.0	7
80	Spectrum of Abnormalities and Clonal Transformation in Germline <i>RUNX1</i> Familial Platelet Disorder and a Comparative Analysis with Somatic <i>RUNX1</i> Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 3003-3003.	0.6	1
81	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019, 134, 558-558.	0.6	19
82	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182.	0.6	1
83	Phenotypic Correlates and Prognostic Outcomes of <i>TET2</i> Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019, 134, 3005-3005.	0.6	0
84	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 1697-1697.	0.6	4
85	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863.	0.6	1
86	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019, 134, 1710-1710.	0.6	0
87	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E144-E146.	2.0	2
88	<i>U2AF1</i> mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. <i>Leukemia</i> , 2018, 32, 2274-2278.	3.3	75
89	<i>U2AF1</i> mutation variants in myelodysplastic syndromes and their clinical correlates. <i>American Journal of Hematology</i> , 2018, 93, E146-E148.	2.0	15
90	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E164-E167.	2.0	1

#	ARTICLE	IF	CITATIONS
91	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018, 32, 1631-1642.	3.3	213
92	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. <i>Leukemia</i> , 2018, 32, 1254-1258.	3.3	42
93	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018, 32, 1200-1210.	3.3	101
94	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18.	2.8	19
95	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , 2018, 32, 1189-1199.	3.3	102
96	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018, 93, 691-697.	2.0	50
97	Mayo CALR mutation type classification guide using alpha helix propensity. <i>American Journal of Hematology</i> , 2018, 93, E128-E129.	2.0	18
98	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. <i>Blood Cancer Journal</i> , 2018, 8, 8.	2.8	1
99	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. <i>American Journal of Hematology</i> , 2018, 93, E93-E96.	2.0	27
100	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 835-838.	1.2	32
101	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2018, 93, E103-E107.	2.0	1
102	Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. <i>British Journal of Haematology</i> , 2018, 182, 437-440.	1.2	22
103	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <i>Leukemia</i> , 2018, 32, 1850-1856.	3.3	25
104	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018, 8, 29.	2.8	49
105	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. <i>British Journal of Haematology</i> , 2018, 182, 594-597.	1.2	31
106	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018, 93, 348-355.	2.0	94
107	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-risk patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 678-681.	1.2	19
108	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. <i>American Journal of Hematology</i> , 2018, 93, E61-E64.	2.0	31

#	ARTICLE	IF	CITATIONS
109	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318.	0.8	373
110	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 1769-1770.	0.8	249
111	MPL-mutated essential thrombocythemia: a morphologic reappraisal. <i>Blood Cancer Journal</i> , 2018, 8, 121.	2.8	17
112	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018, 8, 118.	2.8	7
113	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1500-1537.	2.3	41
114	Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018, 94, 363-377.	2.0	133
115	Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018, 8, 120.	2.8	1
116	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3</i> mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404.	2.0	3
117	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 82.	2.8	24
118	Mutations and karyotype predict treatment response in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, 1420-1426.	2.0	25
119	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. <i>American Journal of Hematology</i> , 2018, 93, E383-E386.	2.0	2
120	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018, 93, 1474-1484.	2.0	56
121	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018, 2, 370-380.	2.5	90
122	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <i>Blood Advances</i> , 2018, 2, 2964-2972.	2.5	68
123	Genotype-phenotype correlation of hereditary erythrocytosis mutations, a single center experience. <i>American Journal of Hematology</i> , 2018, 93, 1029-1041.	2.0	38
124	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018, 8, 57.	2.8	23
125	Myelofibrosis Treatment Algorithm 2018. <i>Blood Cancer Journal</i> , 2018, 8, 72.	2.8	31
126	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2018, 150, 421-431.	0.4	12

#	ARTICLE	IF	CITATIONS
127	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. <i>American Journal of Hematology</i> , 2018, 93, E235-E238.	2.0	8
128	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1008-1010.	1.5	27
129	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <i>Blood Cancer Journal</i> , 2018, 8, 21.	2.8	26
130	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. <i>American Journal of Hematology</i> , 2018, 93, 1461-1466.	2.0	24
131	How I treat myelofibrosis after failure of JAK inhibitors. <i>Blood</i> , 2018, 132, 492-500.	0.6	40
132	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1363-1374.	1.4	20
133	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). <i>Blood</i> , 2018, 132, 578-578.	0.6	5
134	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. <i>Blood</i> , 2018, 132, 4301-4301.	0.6	1
135	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018, 132, 3035-3035.	0.6	1
136	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018, 132, 3040-3040.	0.6	1
137	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2018, 132, 1773-1773.	0.6	3
138	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018, 132, 1821-1821.	0.6	12
139	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018, 132, 4300-4300.	0.6	0
140	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 2722-2722.	0.6	2
141	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018, 132, 3034-3034.	0.6	0
142	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. <i>Blood</i> , 2018, 132, 5440-5440.	0.6	1
143	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018, 132, 1761-1761.	0.6	4
144	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018, 132, 4287-4287.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. <i>Blood</i> , 2018, 132, 582-582.	0.6	0
146	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018, 132, 1767-1767.	0.6	0
147	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018, 132, 4344-4344.	0.6	0
148	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. <i>Blood</i> , 2018, 132, 3050-3050.	0.6	0
149	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018, 132, 3033-3033.	0.6	0
150	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. <i>Blood</i> , 2018, 132, 4291-4291.	0.6	0
151	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018, 132, 3036-3036.	0.6	0
152	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , 2018, 132, 3100-3100.	0.6	0
153	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689.	0.6	0
154	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018, 132, 3044-3044.	0.6	0
155	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. <i>Blood</i> , 2018, 132, 1771-1771.	0.6	0
156	The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 454-459.	2.0	12
157	Monocytosis in polycythemia vera: Clinical and molecular correlates. <i>American Journal of Hematology</i> , 2017, 92, 640-645.	2.0	40
158	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. <i>American Journal of Hematology</i> , 2017, 92, 1311-1317.	2.0	73
159	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627.	2.0	3
160	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. <i>American Journal of Hematology</i> , 2017, 92, 1187-1192.	2.0	21
161	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. <i>American Journal of Hematology</i> , 2017, 92, 1193-1197.	2.0	27
162	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, E5-E6.	2.0	45

#	ARTICLE	IF	CITATIONS
163	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. <i>Blood Cancer Journal</i> , 2017, 7, 657.	2.8	13
164	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). <i>Blood Cancer Journal</i> , 2017, 7, 658.	2.8	16
165	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. <i>Blood Advances</i> , 2016, 1, 21-30.	2.5	243
166	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the <i>FIP1L1-EPDGFR</i> mutation. <i>American Journal of Hematology</i> , 2016, 91, E10-1.	2.0	20
167	Systemic mastocytosis: evolving lessons from large patient registry datasets. <i>American Journal of Hematology</i> , 2016, 91, 654-655.	2.0	4
168	Next generation sequencing in systemic mastocytosis: Derivation of a mutation augmented clinical prognostic model for survival. <i>American Journal of Hematology</i> , 2016, 91, 888-893.	2.0	60
169	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. <i>Annals of Hematology</i> , 2016, 95, 1185-1189.	0.8	13
170	<i>ASXL1</i> and <i>CBL</i> mutations are independently predictive of inferior survival in advanced systemic mastocytosis. <i>British Journal of Haematology</i> , 2016, 175, 534-536.	1.2	25
171	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2016, 91, 503-506.	2.0	47
172	Concurrent activating <i>KIT</i> mutations in systemic mastocytosis. <i>British Journal of Haematology</i> , 2016, 173, 153-156.	1.2	12
173	Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2016, 91, 1146-1159.	2.0	88
174	Targeted next generation sequencing of <i>PDGFRB</i> rearranged myeloid neoplasms with monocytosis. <i>American Journal of Hematology</i> , 2016, 91, E12-4.	2.0	20
175	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016, 128, 1123-1123.	0.6	4
176	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016, 128, 2798-2798.	0.6	3
177	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. <i>Blood</i> , 2016, 128, 3113-3113.	0.6	17
178	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. <i>Blood</i> , 2016, 128, 3115-3115.	0.6	1
179	Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016, 128, 4245-4245.	0.6	9
180	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. <i>Blood</i> , 2016, 128, 4247-4247.	0.6	2

#	ARTICLE	IF	CITATIONS
181	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. <i>Blood</i> , 2016, 128, 4248-4248.	0.6	1
182	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. <i>Blood</i> , 2016, 128, 4249-4249.	0.6	3
183	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. <i>Blood</i> , 2016, 128, 948-948.	0.6	6
184	Initial presentation of CNS-restricted acute lymphoblastic B cell leukaemia as peripheral polyneuropathy. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016214645.	0.2	1
185	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. <i>Blood</i> , 2016, 128, 3129-3129.	0.6	0
186	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 1996-1996.	0.6	0
187	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. <i>Blood</i> , 2016, 128, 4259-4259.	0.6	0
188	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. <i>Blood</i> , 2016, 128, 1986-1986.	0.6	0
189	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. <i>Blood</i> , 2016, 128, 5534-5534.	0.6	1
190	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. <i>Blood</i> , 2016, 128, 3111-3111.	0.6	1
191	The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 3120-3120.	0.6	0
192	Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. <i>British Journal of Haematology</i> , 2015, 171, 875-879.	1.2	5
193	<i>ASXL1</i> mutations are frequent and prognostically detrimental in <i>CSF3R</i> -mutated chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 653-656.	2.0	76
194	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. <i>Nature Medicine</i> , 2015, 21, 1473-1480.	15.2	128
195	Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2015, 90, 250-262.	2.0	73
196	Myeloproliferative Neoplasms. <i>JAMA Oncology</i> , 2015, 1, 97.	3.4	266
197	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	3.4	362
198	Primary Myelodysplastic Syndromes. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1623-1638.	1.4	16

#	ARTICLE	IF	CITATIONS
199	Momelotinib treatmentâ€emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. British Journal of Haematology, 2015, 169, 77-80.	1.2	56
200	Morphologically Occult Systemic Mastocytosis in Bone Marrow. American Journal of Clinical Pathology, 2015, 144, 493-502.	0.4	17
201	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. Blood, 2015, 126, 1599-1599.	0.6	1
202	Spectrum of Mutations Associated with Hereditary Erythrocytosis. Blood, 2015, 126, 2140-2140.	0.6	2
203	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	0.6	1
204	Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype. Blood, 2015, 126, 2819-2819.	0.6	1
205	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. Blood, 2015, 126, 350-350.	0.6	1
206	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood, 2015, 126, 354-354.	0.6	14
207	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. Blood, 2015, 126, 4078-4078.	0.6	1
208	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. Blood, 2015, 126, 828-828.	0.6	2
209	Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival. Blood, 2015, 126, 1611-1611.	0.6	0
210	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. Blood, 2015, 126, 4062-4062.	0.6	0
211	Molecular Correlates of Anemia in Primary Myelofibrosis. Blood, 2015, 126, 4068-4068.	0.6	0
212	CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. Blood, 2015, 126, 2802-2802.	0.6	0
213	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875.	0.6	0
214	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. Blood, 2015, 126, 2805-2805.	0.6	9
215	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882.	0.6	2
216	Is there a role for JAK inhibitors in <i>BCR-ABL1</i>-negative myeloproliferative neoplasms other than myelofibrosis?. Leukemia and Lymphoma, 2014, 55, 2706-2711.	0.6	5

#	ARTICLE	IF	CITATIONS
217	Drug-drug interaction between bosutinib and warfarin. <i>Leukemia and Lymphoma</i> , 2014, 55, 2213-2214.	0.6	3
218	CALR mutations and a new diagnostic algorithm for MPN. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 125-126.	12.5	53
219	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. <i>American Journal of Hematology</i> , 2014, 89, E121-4.	2.0	176
220	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014, 124, 2507-2513.	0.6	575
221	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. <i>Blood</i> , 2014, 124, 2465-2466.	0.6	135
222	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014, 124, 3021-3023.	0.6	112
223	Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 612-624.	2.0	71
224	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	0.6	286
225	Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. <i>American Journal of Hematology</i> , 2013, 88, 312-316.	2.0	64
226	How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to) <i>Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 3</i>	0.6	80
227	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	0.6	122
228	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 104-104.	0.6	3
229	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013, 122, 108-108.	0.6	31
230	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 109-109.	0.6	5
231	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013, 122, 2821-2821.	0.6	1
232	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. <i>Blood</i> , 2013, 122, 2830-2830.	0.6	1
233	Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). <i>Blood</i> , 2013, 122, 4047-4047.	0.6	19
234	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013, 122, 4049-4049.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood, 2013, 122, 662-662.	0.6	11
236	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. Blood, 2013, 122, 664-664.	0.6	19
237	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	0.6	3
238	Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis. Blood, 2013, 122, 2824-2824.	0.6	0
239	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. Blood, 2013, 122, 4060-4060.	0.6	0
240	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048.	0.6	0
241	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955.	0.6	0
242	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	0.6	0
243	One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2012, 87, 25-33.	1.4	181
244	Systemic Mastocytosis. Hematology/Oncology Clinics of North America, 2012, 26, 1117-1128.	0.9	19
245	Treatment of refractory idiopathic hypereosinophilic syndrome: Pitfalls and progress with use of novel drugs. American Journal of Hematology, 2012, 87, 703-706.	2.0	14
246	Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 401-411.	2.0	57
247	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. Blood, 2012, 120, 178-178.	0.6	13
248	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. Blood, 2012, 120, 2836-2836.	0.6	4
249	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. Blood, 2012, 120, 2837-2837.	0.6	10
250	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. Blood, 2012, 120, 2851-2851.	0.6	5
251	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. Blood, 2012, 120, 2867-2867.	0.6	3
252	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. Blood, 2012, 120, 1751-1751.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. <i>Blood</i> , 2012, 120, 1711-1711.	0.6	0
254	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥1% Ring Sideroblasts.. <i>Blood</i> , 2012, 120, 2803-2803.	0.6	0
255	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. <i>Blood</i> , 2012, 120, 3790-3790.	0.6	0
256	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. <i>Blood</i> , 2012, 120, 430-430.	0.6	0
257	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 423-423.	0.6	0
258	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. <i>Blood</i> , 2012, 120, 2831-2831.	0.6	0
259	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. <i>Blood</i> , 2012, 120, 1742-1742.	0.6	9
260	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. <i>Blood</i> , 2012, 120, 2849-2849.	0.6	0
261	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 392-397.	0.8	854
262	Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1356-1363.	0.8	485
263	Neurologic symptoms and diagnosis in adults with mast cell disease. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 570-574.	0.6	30
264	Targeting myeloproliferative neoplasms with JAK inhibitors. <i>Current Opinion in Hematology</i> , 2011, 18, 105-110.	1.2	38
265	Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. <i>Blood</i> , 2011, 118, 4595-4598.	0.6	64
266	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	0.8	724
267	Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. <i>American Journal of Hematology</i> , 2011, 86, 343-345.	2.0	27
268	Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 362-371.	2.0	31
269	Infrequent occurrence of <i>MPL</i> exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. <i>American Journal of Hematology</i> , 2011, 86, 701-702.	2.0	29
270	Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies. <i>American Journal of Hematology</i> , 2011, 86, 1013-1016.	2.0	25

#	ARTICLE	IF	CITATIONS
271	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. <i>Cancer</i> , 2011, 117, 4869-4877.	2.0	50
272	Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2011, 29, 789-796.	0.8	369
273	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011, 118, 1759-1759.	0.6	1
274	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. <i>Blood</i> , 2011, 118, 277-277.	0.6	7
275	SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,. <i>Blood</i> , 2011, 118, 3838-3838.	0.6	12
276	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011, 118, 3849-3849.	0.6	16
277	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. <i>Blood</i> , 2011, 118, 3850-3850.	0.6	1
278	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. <i>Blood</i> , 2011, 118, 460-460.	0.6	2
279	Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis. , 2011, , 205-221.		0
280	Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases. <i>Blood</i> , 2011, 118, 2806-2806.	0.6	0
281	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. <i>Blood</i> , 2011, 118, 3795-3795.	0.6	0
282	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 5158-5158.	0.6	0
283	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011, 118, 1752-1752.	0.6	2
284	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. <i>Blood</i> , 2011, 118, 3833-3833.	0.6	0
285	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 1756-1756.	0.6	1
286	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. <i>Blood</i> , 2011, 118, 971-971.	0.6	0
287	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. <i>Blood</i> , 2011, 118, 5154-5154.	0.6	0
288	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. <i>Blood</i> , 2011, 118, 2807-2807.	0.6	0

#	ARTICLE	IF	CITATIONS
289	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. <i>Blood</i> , 2011, 118, 1751-1751.	0.6	5
290	Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. <i>Current Opinion in Hematology</i> , 2010, 17, 125-132.	1.2	84
291	WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. <i>Blood</i> , 2010, 115, 150-151.	0.6	78
292	Proposal for a revised classification of systemic mastocytosis. <i>Blood</i> , 2010, 115, 2720-2721.	0.6	17
293	Response criteria in systemic mastocytosis: moving forward with practical assessment that reflects meaningful health outcome. <i>European Journal of Haematology</i> , 2010, 85, no-no.	1.1	0
294	<i>LNK</i> Mutations in <i>JAK2</i> Mutationâ€“Negative Erythrocytosis. <i>New England Journal of Medicine</i> , 2010, 363, 1189-1190.	13.9	138
295	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. <i>New England Journal of Medicine</i> , 2010, 363, 1117-1127.	13.9	1,046
296	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. <i>Blood</i> , 2010, 116, 3068-3068.	0.6	3
297	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2010, 116, 3070-3070.	0.6	7
298	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. <i>Blood</i> , 2010, 116, 4105-4105.	0.6	4
299	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. <i>Blood</i> , 2010, 116, 4112-4112.	0.6	3
300	Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden. <i>Blood</i> , 2010, 116, 459-459.	0.6	4
301	A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. <i>Blood</i> , 2010, 116, 460-460.	0.6	22
302	Epigenomic Profiling of Myeloproliferative Diseases Reveal Idiopathic Myelofibrosis as An Epigenetically Distinct Subgroup and Highlights the Epigenetic Effects of Jak2V617F Mutation. <i>Blood</i> , 2010, 116, 627-627.	0.6	2
303	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. <i>Blood</i> , 2010, 116, 4104-4104.	0.6	1
304	Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients. <i>Blood</i> , 2010, 116, 4122-4122.	0.6	0
305	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. <i>Blood</i> , 2010, 116, 4109-4109.	0.6	1
306	Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype. <i>Blood</i> , 2010, 116, 3069-3069.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens. <i>Blood</i> , 2010, 116, 4094-4094.	0.6	0
308	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 4009-4009.	0.6	0
309	Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon α , hydroxyurea, imatinib mesylate or 2 β -chlorodeoxyadenosine. <i>American Journal of Hematology</i> , 2009, 84, 790-794.	2.0	166
310	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. <i>Leukemia Research</i> , 2009, 33, 1199-1203.	0.4	203
311	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. <i>Blood</i> , 2009, 113, 5727-5736.	0.6	484
312	Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. <i>Blood</i> , 2009, 114, 3769-3772.	0.6	157
313	IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.. <i>Blood</i> , 2009, 114, 2909-2909.	0.6	9
314	Primary eosinophilic disorders: A concise review. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 37-43.	1.2	8
315	JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients. <i>Mayo Clinic Proceedings</i> , 2008, 83, 457-459.	1.4	47
316	Phase II Study of Dasatinib in Philadelphia Chromosome α -Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. <i>Clinical Cancer Research</i> , 2008, 14, 3906-3915.	3.2	151
317	Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. <i>Blood</i> , 2008, 111, 2785-2789.	0.6	135
318	Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424. <i>Blood</i> , 2008, 112, 2802-2802.	0.6	12
319	The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2. <i>Blood</i> , 2008, 112, 2804-2804.	0.6	12
320	TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFR α in Vitro. <i>Blood</i> , 2008, 112, 2807-2807.	0.6	1
321	Prognostically Relevant Breakdown of 138 Patients with Systemic Mastocytosis Associated with Another Hematological Malignancy. <i>Blood</i> , 2008, 112, 2808-2808.	0.6	0
322	Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. <i>Cancer</i> , 2007, 109, 2279-2284.	2.0	149
323	Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. <i>British Journal of Haematology</i> , 2007, 138, 354-358.	1.2	139
324	Extending JAK2V617F and MPLW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes. <i>Stem Cells</i> , 2007, 25, 2358-2362.	1.4	65

#	ARTICLE	IF	CITATIONS
325	Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. Blood, 2007, 110, 3546-3546.	0.6	2
326	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. Blood, 2007, 110, 558-558.	0.6	28
327	Systemic Mastocytosis: A Concise Clinical and Laboratory Review. Archives of Pathology and Laboratory Medicine, 2007, 131, 784-791.	1.2	49
328	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≤ 10 g/dL.. Blood, 2007, 110, 3555-3555.	0.6	0
329	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. Blood, 2007, 110, 676-676.	0.6	2
330	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. Blood, 2007, 110, 2550-2550.	0.6	0
331	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. Blood, 2007, 110, 3191-3191.	0.6	0
332	A role for tryptase in myeloid disorders?. Leukemia and Lymphoma, 2006, 47, 789-790.	0.6	1
333	Dysregulated EVI1 expression in myeloid malignancies. Leukemia and Lymphoma, 2006, 47, 2443-2444.	0.6	1
334	Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood, 2006, 107, 4572-4573.	0.6	30
335	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 2006, 108, 3472-3476.	0.6	963
336	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. Blood, 2006, 108, 2680-2680.	0.6	5
337	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. Blood, 2006, 108, 116-116.	0.6	6
338	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. Blood, 2006, 108, 661-661.	0.6	0
339	Idiopathic Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFR α Status, and Clinical Course.. Blood, 2006, 108, 2701-2701.	0.6	0
340	Low Incidence of FIP1L1-PDGFR α in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. Blood, 2005, 106, 2590-2590.	0.6	1
341	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leukemia Research, 2004, 28, 47-52.	0.4	24
342	Clinical, genetic, and therapeutic insights into systemic mast cell disease. Current Opinion in Hematology, 2004, 11, 58-64.	1.2	73

#	ARTICLE	IF	CITATIONS
343	FIP1L1-PDGFR α fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. <i>Blood</i> , 2004, 104, 3038-3045.	0.6	297
344	FIP1L1-PDGFR α and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. <i>Haematologica</i> , 2004, 89, 871-3.	1.7	45
345	Chronic basophilic leukemia: a distinct clinico-pathologic entity?. <i>European Journal of Haematology</i> , 2003, 71, 18-22.	1.1	25
346	Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. <i>Leukemia Research</i> , 2003, 27, 739-742.	0.4	40
347	Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. <i>British Journal of Haematology</i> , 2003, 120, 691-694.	1.2	21
348	Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. <i>Leukemia Research</i> , 2003, 27, 883-885.	0.4	79
349	2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell Histiocytosis. <i>Mayo Clinic Proceedings</i> , 2003, 78, 301-306.	1.4	75
350	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. <i>Blood</i> , 2003, 101, 827-830.	0.6	69
351	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. <i>Blood</i> , 2003, 101, 3391-3397.	0.6	206
352	CHIC2 deletion, a surrogate for FIP1L1-PDGFR α fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. <i>Blood</i> , 2003, 102, 3093-3096.	0.6	368
353	Systemic Mast Cell Disease Without Associated Hematologic Disorder: A Combined Retrospective and Prospective Study. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1169-1175.	1.4	38
354	Primer on Medical Genomics Part IV: Expression Proteomics. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1185-1196.	1.4	25